I am a pediatric oncologist who specializes in bone marrow transplantation. I treat children and young adults who have hematologic malignancies such as leukemia, disorders of the bone marrow that impair the ability to make normal blood cells, and disorders of the immune system that impair the body’s ability to fight infection.
My research focus is on the development of novel treatment approaches for leukemia and lymphoma that do not respond to current therapies. Specifically, my colleagues and I use genetic manipulation of immune cells to recognize and kill cancer cells. This is a promising form of gene therapy and is currently being tested in clinical trials at Memorial Sloan Kettering Cancer Center for children and adults with high-risk or relapsed hematologic cancers. Through these highly innovative studies, we hope to provide a novel and successful treatment option for all patients with cancer.
- Clinical Expertise: Pediatric Oncology; Allogeneic and Autologous Hematopoietic Stem Cell Transplantation; Adoptive T Cell Immunotherapy
- Languages Spoken: English
- Education: MD, Georgetown University School of Medicine
- Residencies: Floating Hospital for Children, Tufts University Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: General Pediatrics; Pediatric Hematology/Oncology
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Kevin J. Curran
- A Phase I Study of Immunotherapy with Genetically Modified T Cells Targeting CD19 in Pediatric and Young Adult Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia
- A Phase I Study of Modified T Cells Targeted to CD19-Positive Acute Lymphoblastic Leukemia Relapsing After Allogeneic Stem Cell Transplantation